Jan 01,2019

Flatiron Signs Definitive Agreement to Acquire the Assets of American Family Archives & Chronicles, Inc.

Flatiron Health has entered into a definitive agreement to acquire the assets developed by American Family Archives & Chronicles, Inc (AFAC). Flatiron has been working with AFAC for over three years, and they believe that the addition of their team will help Flatiron continue to develop a high-quality, comprehensive mortality dataset.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 07,2019

CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments. Integration with the CytoReason disease model empowers the study analytics and allows the model to learn and improve, leading to robust target discovery, drug response biomarkers and indication selection.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 20,2019

MetaOptima attending the Professional Certificate of Skin Cancer Medicine

MetaOptima's Australia team will be participating of the upcoming Professional Certificate of Skin Cancer Medicine these February 23rd & 24th in Melbourne. This course is designed to equip GPs with a powerful practical approach on how to diagnose and advise on melanoma and other skin conditions.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 22,2019

Success Or Failure: Where Is Teledermatology Set To Stand? - Part 2

Part I of this article from MetaOptioma and DermEngine team discussed how in spite of teledermatology’s relatively short history it rapidly became a widely used technique. Part II will explain how two nations successfully overcame administration barriers similar to those which the U.S. is currently facing. This will be done by discussing the factors which supplemented widespread teledermatology adoption, and also introducing how other techniques may support its future promotion.

#telehealth

#ai/software

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 28,2019

Kaiku Health and Amgen roll out digital patient support for Multiple Myeloma

Finnish health data science company Kaiku Health that develops personalised digital health interventions in oncology, and one of the world’s leading biotechnology companies Amgen have partnered to advance the use of digital symptom management and personalised patient support in routine care of Multiple Myeloma in Finland. Multiple Myeloma patients suffer from several disease- or treatment-related symptoms. Thus, symptom management is an important part of treating MM, and easing symptoms helps in improving patients’ quality of life.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2019

DermEngine’s Compliance with Health Information Privacy in New Zealand

Dermatology platforms dealing with this sort of information such as DermEngine, need to guarantee the full adherence to the rules and regulations outlined in the code if they are to comply with New Zealand’s management of medical-related information. Consequently, there are several rules that need to be closely observed and which exercise control over landmark points in the flow of patient information.

PRODUCT

#platform

View Analyst & Ambassador Comments
Go to original news
Feb 14,2019

Success Or Failure: Where Is Teledermatology Set To Stand? - Part 1

Currently, the health industry is overloaded with patients seeking quality medical care.2 Seeing as over 75% of U.S. citizens have access to a smartphone, it follows that this technology can be utilized for patients to generate and communicate valuable information with their physician.3 By combining the connective power of telecommunication with dermatology care, teledermatology services hold the potential to be implemented around the globe. The introduction of intelligent dermatology software such as DermEngine has provided two alternative consultation methods to the traditional face-to-face consultations: live-interactive and store-and-forward.

#telehealth

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 01,2019

The FDA and Flatiron Health Expand Real-World Data Cancer Research Collaboration

Flatiron Health and the Information Exchange and Data Transformation (INFORMED) Program at the U.S. Food and Drug Administration (FDA) today announced a two-year renewal and expansion of their research collaboration agreement. The collaboration, which began in 2016, has enabled the FDA to better understand how real-world evidence (RWE), derived from de-identified patient datasets curated from electronic health records, can support regulatory decision-making.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Feb 04,2019

The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients

In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for the Cancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge: their pioneering grants initiative designed to support the implementation of projects worldwide that address the specific needs of women with metastatic breast cancer in local communities – many of which extend beyond treatment. A total of US$275,000 in funding will be awarded to 10 new organizations, bringing the SPARC awardees network to 50 cancer organizations from all across the globe with a total funding of US$1,565,000.

View Analyst & Ambassador Comments
Go to original news
Feb 28,2019

Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019

Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY